Instead of acknowledging that the drug's time-release mechanism was failing, Purdue's marketing team told doctors that their patients were experiencing "breakthrough pain". Their proposed solution was not to switch medications, but to . This "individualizing of the dose" bypassed standard medical warnings that a patient might be developing a dangerous tolerance or addiction. Key Characters Caught in the Crisis

The episode highlights how this strategy devastated real lives through fictionalized avatars of the crisis:

In the 2021 Hulu limited series Dopesick , the second episode—titled —serves as a pivotal turning point in the narrative. It exposes the marketing machinery of Purdue Pharma as they encounter a fatal flaw in their "miracle drug," OxyContin, and choose to rebrand a medical failure into a lucrative sales strategy. The Rebranding of a Medical Failure

Historically, the term "breakthrough pain" referred to a transitory flare of intense pain in patients already managed on a stable opioid regimen, typically those with cancer. However, in the series, Purdue Pharma executives, led by , weaponize the term to address a growing problem: OxyContin was not lasting the promised 12 hours for many patients.